Podcasts about amikacin

Dhineli Perera talks to infectious diseases physician and clinical microbiologist Carly Hughes about the latest recommendations for aminoglycoside use in Australia. They discuss indications for parenteral aminoglycosides, drug selection, dosing and therapeutic drug monitoring. Read the full article by Carly and her co-authors in Australian Prescriber.

Send us a textCurious about the scientific evidence behind treating joint infections in foals? This eye-opening conversation with Dr. David Wallace explores groundbreaking research validating common clinical practices while revealing surprising limitations.Septic joints in foals present a clinical challenge requiring both local and systemic antimicrobial therapy. Until now, veterinarians have largely extrapolated treatment protocols from adult horses without solid evidence supporting these approaches in neonatal patients. Dr. Wallace's research addresses this critical knowledge gap, examining whether concurrent intravenous regional limb perfusion (IRLP) and systemic amikacin administration achieves therapeutic concentrations in both compartments.The results offer reassurance that splitting the amikacin dose—one-third for regional perfusion and two-thirds systemically—effectively treats both joint infections and underlying systemic disease. Most joints achieved therapeutic concentrations, though significant challenges emerged with hind limb perfusions. The metatarsophalangeal joint consistently failed to reach target levels, revealing important technical limitations around tourniquet placement and vascular integrity that clinicians should consider when treating these patients.This conversation highlights numerous opportunities for future research, from evaluating alternative tourniquet designs to determining appropriate dose adjustments for multiple affected limbs. Dr. Wallace emphasizes that individual patient response remains paramount, reminding us that "foals are not small horses" and require specialized approaches. Whether you're a practicing veterinarian, student, or equine enthusiast, this episode provides valuable insights into evidence-based care for our youngest equine patients. Subscribe now to stay updated on the latest advances in veterinary medicine!JAVMA article: https://doi.org/10.2460/javma.24.10.0678INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Welcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. Mike and John Fralick discuss two recent papers - the Balance Trial and the role of inhaled amikacin in preventing VAP. Two papers, here we go!Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia (0:00 – 8:24).Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (the Balance Trial) (8:24 – 17:24).And for the Good Stuff:The Tragically Hip: No Dress Rehearsal (17:24 – 18:30).www.powercalc.ca (18:30 – 20:06)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode, we discuss the recently published RCT AMIKINHAL, which tested the efficacy of inhaled amikacin in preventing VAP in ICU patients who were ventilated for> 72 hours. Although, this trail demonstrated reduced incidence of VAP in intervention arm, it's premature to adopt these practices widely in intensive care.

Show notes at pharmacyjoe.com/episode866. In this episode, I’ll discuss inhaled amikacin to prevent VAP. The post 866: Can 3 Days of Inhaled Amikacin Prevent VAP? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode866. In this episode, I’ll discuss inhaled amikacin to prevent VAP. The post 866: Can 3 Days of Inhaled Amikacin Prevent VAP? appeared first on Pharmacy Joe.

In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G 

This podcast episode is part of a multimedia program reviewing the management of nontuberculous mycobacterial lung disease (NTM-LD). Tune in to hear Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC, and Anne O'Donnell, MD, highlight the diagnostic criteria and optimal treatment strategies in patients with NTM-LD. The overview will include: Recommended assessments and tests to appropriately diagnosis NTM-LD in patientsA summary of the current guidelines for the management of NTM-LD, including appropriate monitoring of medications.Guidance on how to individualize treatment plans for patients with NTM-LD based on disease and patient characteristicsPresenters: Jennifer Faber-Gerling, RN, MS, CNS, ANP-BCNurse PractitionerDivision of Mycobacterial and Respiratory InfectionsNational Jewish HealthDenver, ColoradoAnne O'Donnell, MDProfessor of MedicineDivision of Pulmonary, Critical Care, and Sleep MedicineGeorgetown University Medical CenterWashington, DCTo view other program offerings, including a CE-certified on-demand webcast, a Q&A text module, and to download slides, visitpce.is/NTM.

Let's revive an old practice that may one day help you treat uncomplicated cystitis without having to admit your patient to the hospital Click HERE to leave a review of the podcast!Subscribe HERE!References:All references for Episode 80 are found on my Read by QxMD collectionDisclaimer: The information contained within the  ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution,  seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of,  any medical institutions, educational facilities, or other healthcare programs.Support the show

This podcast discusses the paper 'Amikacin induces rapid dose-dependent apoptitic cell death in equine chrondrocytes and synovial cells in vitro’ by Pezzanite et al. 

Dr. John Fleetham sits down with Dr. Kennth Olivier to discuss the findings of his paper published in the AJRCCM this past March

Pseudomonas aeruginosa Eradication and Outcomes: Key Questions

eCystic Fibrosis Review: Featured Cases: Emerging Pathogens in Cystic Fibrosis

Trotz der üblichen prophylaktischen Maßnahmen im Rahmen der Operationsvorbereitung können Erreger nachgewiesenermassen während der Operation ins Auge gelangen. Die perioperative systemische Gabe von Imipenem kann eventuell ins Augeninnere gelangte Erreger sterilisieren, zumindest bis zu einem bestimmten Maximum an Organismen. Im ersten Teil der vorliegenden Arbeit im tierexperimentellen Modell am phaken Kaninchenauge war es möglich, sämtliche mit 100 CFU S. aureus inifizierten Augen zu sterilisieren, falls diese 8 Stunden und eine halbe Stunde vor Infektion, sowie 8 Stunden nach Infektion intravenös Imipenem erhielten. Bei einer Erregermenge von 10 000 CFU waren noch 5 von 6 Augen steril, bei 10 000 CFU nur noch 3 von 6 Augen. Weiterhin scheint es möglich, den Glaskörper durch alleinige intravenöse Imipenemgabe sterilisieren zu können, wenn eine bestimmte Anzahl von intraokulären Keimen nicht überschritten wird. Im zweiten Teil dieser Arbeit wurden Augen mit 1000 CFU S. aureus infiziert und nach 24 Stunden intravenöse Therapie mit Imipenem oder der in der EVS verwendeten Kombination Ceftazidim und Amikazin begonnen. Nach 7 Tagen waren signifikant geringere Erregermengen in den mit Imipenem behandelten Augen festzustellen, als in mit Ceftazidim und Amikazin behandelten oder der unbehandelten Kontrollgruppe. 4 von 6 mit Imipenem therapierten Augen waren zu diesem Zeitpunkt steril. Ob es möglich ist, eine Endophthalmitis in einem derart frühen Stadium zu diagnostizieren und dann intravenös ohne intraokuläre Antibiotikaeingabe befriedigend therapieren zu können ist jedoch fraglich, denn in dieser Studie waren selbst in Augen mit negativem Kulturergebniss massive Entzündungszeichen festzustellen. Im dritten Teil dieser Arbeit stellte sich die intraokuläre Eingabe von Vancomycin und Amikacin als der alleinigen systemischen Imipenemgabe deutlich überlegen heraus, sowohl im Hinblick auf Erregermengen, klinischen Verlauf und histopathologisches Erscheinungsbild. Zu einem frühen Zeitpunkt der Infektion gegeben, können intraokuläres Vancomycin und Amikacin in diesem Tierexperiment relativ klare optische Medien ohne zusätzlich chirurgische Therapie erhalten. In dem hier durchgeführten Experiment erbrachte die zusätzliche intravenöse Therapie mit Imipenem keine messbare Verbesserung gegenüber der alleinigen intravitrealen Therapie mit Vancomycin und Amikacin.

Featured Cases: Emerging Pathogens in Cystic Fibrosis